Although surgical resection plays an integral role in the treatment of malignant gliomas, infiltration of tumor cells into surrounding brain prohibits cure by resection alone.\(^1,2\) Radiotherapy has been shown to improve local control and survival in patients with malignant gliomas.\(^1,3\) Chemotherapy has also been shown to improve survival and recently a multicenter trial demonstrated that radiation administered concomitantly with surgery, conventional fractionated radiation, and high-activity iodine-125 boost brachytherapy as part of a randomized controlled trial. Conclusion: Despite this apparent cause and effect relationship, statistical analysis shows no relationship between these cures and treatment with brachytherapy. Cure of glioblastoma remains rare.

Temporary interstitial brachytherapy allows the precise delivery of a large dose of localized radiation to the region with the highest concentration of infiltrating tumor cells, offering the prospect of improving local control. This modality was appealing in the 1980's and 1990's because of the high spatial localization of the dose and the favorable therapeutic ratio afforded by the low dose rate.\(^10^-12\) There have been some reports of patients diagnosed with GBM have a survival greater than 3 years.\(^9\)


ABSTRACT: Background: Very long term survival after diagnosis of malignant glioma has been described in individual case reports. Survival of more than 10 years is extremely rare, especially when identified in 3 out of 71 patients assigned to one arm of a randomized controlled trial. Patients: Three patients survived 11, 16, and 18 years following the diagnosis of glioblastoma and treatment with surgery, conventional fractionated radiation, and high-activity iodine-125 boost brachytherapy as part of a randomized controlled trial. Conclusion: Despite this apparent cause and effect relationship, statistical analysis shows no relationship between these cures and treatment with brachytherapy. Cure of glioblastoma remains rare.

RÉSUMÉ: Coïncidence vs cause : guérison chez trois patients atteints de glioblastome traités par brachythérapie. Contexte : Quelques patients ayant eu une survie très longue après un diagnostic de gliome malin ont été décrits antérieurement. Une survie de plus de 10 ans est extrêmement rare, d’autant plus qu’on l’a observée chez trois patients d’un groupe de 71 patients assignés au même bras d’une étude contrôlée randomisée. Observations : Trois patients ont survécu 11, 16 et 18 ans respectivement après le diagnostic de glioblastome et leur participation à une étude contrôlée randomisée comparant le traitement par chirurgie, radiothérapie fractionnée conventionnelle et brachythérapie par l’iode-125 comme source de radioactivité de haute activité. Conclusion : Malgré qu’il semble exister ici une relation de cause à effet, l’analyse statistique n’a pas montré de relation entre ces cas de guérison et le traitement par brachythérapie. Les cas de guérison du glioblastome demeurent rares.

From the Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.

Received January 8, 2007. Accepted in final form April 7, 2007.

Reprint requests to: Mark Bernstein, Division of Neurosurgery, Toronto Western Hospital, 399 Bathurst Street, 4th floor, West Wing, Toronto, Ontario, M5T 2S8, Canada.
of enhanced survival benefit with interstitial I-125 brachytherapy.\textsuperscript{10,13} However, the favorable results were biased by a selective group of patients who had other prognostic features associated with longer survival.\textsuperscript{12,14} When studied in two randomized control trials, brachytherapy offered no significant survival benefit over conventional treatment.\textsuperscript{15,16}

In this case study, we document and report three patients diagnosed with glioblastoma who received brachytherapy on the randomized study at our center who continue to enjoy survival for more than 10 years after diagnosis of the disease.

**MATERIALS AND METHODS**

The randomized trial of brachytherapy was designed to compare conventional external radiation therapy alone vs. conventional radiation therapy plus a brachytherapy boost in patients with malignant gliomas, with the primary end point as overall survival.\textsuperscript{15} The inclusion criteria were as follows: 1) biopsy proven supratentorial malignant glioma; 2) age 18-70; 3) KPS >70; 4) no involvement of corpus callosum; and 5) maximum tumor diameter of 6 cm.

The brachytherapy technique has previously been described.\textsuperscript{15} Briefly, brachytherapy was undertaken within two weeks of completing external-beam radiation therapy. Linear plastic catheters were inserted stereotactically and high activity iodine-125 seeds were afterloaded intraoperatively. The intention was to deliver an additional minimum peripheral tumor dose of 60 Gy to all enhancing disease. The study demonstrated no statistically significant difference in the survival curves in the two groups, with the median survival of 13.8 months in the brachytherapy group as compared to 13.2 months in the group without brachytherapy. However, three patients among 71 randomized to the brachytherapy group have survived for an unusually long period. No patients in the 69 patients randomized to the group with conventional radiotherapy alone have enjoyed long survival.

**Case 1**

A 43-year-old female presented in 1995 with headache and left sided mild hemiparesis. She underwent aggressive resection of a right parietal glioblastoma (which appeared typical on imaging and on histology which was reviewed by two neuropathologists). This was followed by conventional radiotherapy and interstitial brachytherapy. At last follow-up in August 2006 the patient has a grossly normal neurological status except for mild dysarthria and KPS of 80. Recent MRI shows some superficial enhancement over the right parietal area which has remained stable (Figure 1).

**Case 2**

A 57-year-old male presented in 1990 with a non-dominant sided parietal syndrome. Imaging showed a typical ring-enhancing right parietooccipital glioblastoma (histological examination confirmed a typical glioblastoma and was reviewed by two neuropathologists). The patient underwent aggressive subtotal resection followed by radiotherapy and subsequently brachytherapy. At last follow-up in October 2006 he has significant gait impairment due to left leg weakness and sensory loss but is well-preserved cognitively. Recent MR, 16 years after surgery shows an area of enhancement at the site of the tumor without mass effect, which has been stable over the last 15 years (Figure 2).

**Case 3**

A 33-year-old male patient presented in 1988 with headache and right sided homonymous hemianopia. Imaging showed a typical looking glioblastoma in the left occipital region and the patient underwent surgical resection of a glioblastoma which was confirmed by two neuropathologists. He was treated with boost brachytherapy and 24 months after brachytherapy underwent aggressive reoperation for predominantly radiation necrosis. The patient has remained well with KPS of 100 and MR follow-up remains devoid of tumor residue or recurrence.

**DISCUSSION**

Treatment of high grade gliomas remains a challenging clinical problem despite advances in neurosurgery, delivery of radiation, and novel chemotherapeutic agents. Radiation provides greater increases in survival than any other treatment modality.\textsuperscript{17} However increases in the radiation dose over 60 Gy have not resulted in additional improvement in survival.\textsuperscript{13} In the case of fractionated external beam radiotherapy, the lack of benefit from an additional dose is limited by injury to the normal brain. Brachytherapy was developed in an attempt to address
and fortunately at no significant cost to quality.

Nevertheless, the median survival in patients with GBM has not been improved by conventional radiation, and the results of the two randomized studies that were disappointing, showing that brachytherapy offers no significant improvement of survival. Recently a multi-institutional Gliasite brachytherapy trial showed a modest survival benefit in a group of patients with recurrent malignant gliomas.

It has been reported that aggressive treatment of GBM is associated with a survival benefit while conventionally treated patients with GBM have both a short median survival and a very small chance of long-term survival. Also, when examining characteristics that are associated with better outcome, younger age (mean 43.5) and KPS >70 prove to be important predictors. The usefulness of maximal surgical resection is unknown as no prospective randomized trial has been done, although some studies conclude that patients having aggressive tumor resection have longer survival. Histological characteristics that are associated with enhanced survival include fewer mitotic figures as well as a lower Ki-67 score and the presence of oligodendrogial features. Nevertheless, the median survival in all these patients does not exceed 18 to 20 months in the best situation.

The new molecular studies analyzing the methylation status of the MGMT show a significant but modest augmentation of survival. Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy. Their median survival was 21.7 months, as compared with 15.3 months among those who were assigned to radiotherapy only. Those who did not have a methylated MGMT promoter did not have a statistically significant prolongation of survival from the combination of temozolomide and radiotherapy.

In the 71 patients randomized to brachytherapy along with surgery and radiotherapy, we were able to find three survivors essentially cured of disease whereas in the 69 patients randomized to the surgery and radiotherapy group, there were no long-term survivors (maximum survival 26 months). These three patients had typical glioblastomas on imaging and histological examination but we have no molecular analysis of these tumors.

How should this interesting finding be interpreted? There is a 4.2% rate of long survival in the brachytherapy group as compared to 0 in the other group (p=0.24; Fisher’s exact test). Very long-term survival after glioblastoma treatment has been described in individual cases but this is the first study which reports a 4.2% 10-year survival in a defined group of patients treated in a specific way. However, we cannot state that the prolonged survival is due to the treatment with brachytherapy and in fact the statistical analysis suggests no relationship. Whether these three patients represent a trend is matter for speculation only.

Is there a biologically or clinically select group of patients who enjoy an unusual survival rate? These three patients were different in terms of sex, age, preoperative Karnofsky score, and even postoperative neurological status. The most important similarity was the relatively focal pattern of tumor enhancement. The new molecular studies analyzing the methylation status of the MGMT promoter show a survival benefit in patients with GBM treated in a specific way. However, we cannot state that the long-term survivors are those who have a methylated MGMT promoter. This may be because the limited number of survivors in this study and the abovementioned substantial differences, make such an evaluation impossible. With newer magnetic resonance imaging techniques we may be able to identify patients with extremely focal disease who may stand to benefit from such focal aggressive approaches.

As pointed out above, radiation therapy has a prominent role in the treatment of primary intracranial malignant tumors. Although the long survival rate of 4.2% is a modest percentage in the brachytherapy group, this observation may warrant more attention to try to identify that subset of individuals with a higher likelihood of significant response to brachytherapy (or nowadays non-invasive focused high-dose radiation such as with radiosurgery). To date, there are no reports of very long survival following radiosurgery for glioblastomas.

Three very long-term survivors (10 years) with glioblastoma were identified in the brachytherapy arm of a randomized trial of brachytherapy used as a boost in the initial treatment of malignant glioma. Numbers are too few to be able to statistically define a subgroup that might have benefited from brachytherapy in this series, and the same limitation will obtain for observations of rare long-term survivors in other series. The authors are not recommending brachytherapy or other focused radiation modalities for the treatment of malignant gliomas based on these observations. The important message is for us clinicians to continue to make every attempt to identify subgroups of patients who may benefit from such focal aggressive approaches.

Some of these limitations. The promise of improved survival has been dampened by the high rate of radiation necrosis and tumor recurrence inspite of marginal improvement in local control, and fortunately at no significant cost to quality of life. Despite some encouraging results from a few single arm studies which reported an improved survival with brachytherapy, the results of the two randomized studies were disappointing, showing that brachytherapy offers no significant improvement of survival. Recently a multi-institutional Gliasite brachytherapy trial showed a modest survival benefit in a group of patients with recurrent malignant gliomas.

It has been reported that aggressive treatment of GBM is associated with a survival benefit while conventionally treated patients with GBM have both a short median survival and a very small chance of long-term survival. Also, when examining characteristics that are associated with better outcome, younger age (mean 43.5) and KPS >70 prove to be important predictors. The usefulness of maximal surgical resection is unknown as no prospective randomized trial has been done, although some studies conclude that patients having aggressive tumor resection have longer survival. Histological characteristics that are associated with enhanced survival include fewer mitotic figures as well as a lower Ki-67 score and the presence of oligodendrogial features. Nevertheless, the median survival in all these patients does not exceed 18 to 20 months in the best situation.

The new molecular studies analyzing the methylation status of the MGMT show a significant but modest augmentation of survival. Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy. Their median survival was 21.7 months, as compared with 15.3 months among those who were assigned to radiotherapy only. Those who did not have a methylated MGMT promoter did not have a statistically significant prolongation of survival from the combination of temozolomide and radiotherapy.

In the 71 patients randomized to brachytherapy along with surgery and radiotherapy, we were able to find three survivors essentially cured of disease whereas in the 69 patients randomized to the surgery and radiotherapy group, there were no long-term survivors (maximum survival 26 months). These three patients had typical glioblastomas on imaging and histological examination but we have no molecular analysis of these tumors.

How should this interesting finding be interpreted? There is a 4.2% rate of long survival in the brachytherapy group as compared to 0 in the other group (p=0.24; Fisher’s exact test). Very long-term survival after glioblastoma treatment has been described in individual cases but this is the first study which reports a 4.2% 10-year survival in a defined group of patients treated in a specific way. However, we cannot state that the prolonged survival is due to the treatment with brachytherapy and in fact the statistical analysis suggests no relationship. Whether these three patients represent a trend is matter for speculation only.

Is there a biologically or clinically select group of patients who enjoy an unusual survival rate? These three patients were different in terms of sex, age, preoperative Karnofsky score, and even postoperative neurological status. The most important similarity was the relatively focal pattern of tumor enhancement. It would be important to find a specific subgroup of patients who might benefit from adjuvant brachytherapy (or other focused radiation) but the limited number of survivors in this study and the abovementioned substantial differences, make such an evaluation impossible. With newer magnetic resonance imaging techniques we may be able to identify patients with extremely focal disease who may stand to benefit from such focal aggressive approaches.

As pointed out above, radiation therapy has a prominent role in the treatment of primary intracranial malignant tumors. Although the long survival rate of 4.2% is a modest percentage in the brachytherapy group, this observation may warrant more attention to try to identify that subset of individuals with a higher likelihood of significant response to brachytherapy (or nowadays non-invasive focused high-dose radiation such as with radiosurgery). To date, there are no reports of very long survival following radiosurgery for glioblastomas.

Three very long-term survivors (>10 years) with glioblastoma were identified in the brachytherapy arm of a randomized trial of brachytherapy used as a boost in the initial treatment of malignant glioma. Numbers are too few to be able to statistically define a subgroup that might have benefited from brachytherapy in this series, and the same limitation will obtain for observations of rare long-term survivors in other series. The authors are not recommending brachytherapy or other focused radiation modalities for the treatment of malignant gliomas based on these observations. The important message is for us clinicians to continue to make every attempt to identify subgroups of patients who may benefit from such focal aggressive approaches.

Figure 2: MRI 16 years after resection, conventional radiation, and brachytherapy of a right parietooccipital glioblastoma, in a presently 74-year-old man. There is some enhancement around the surgical site but no new change has been observed over the last 10 years.
with better prognoses from aggressive therapies. It also reminds us to be ever aware that apparent cause and effect relationships in clinical medicine may still simply be coincidences.

**REFERENCES**


